Oxford BioDynamics to assess EpiSwitch in prostate cancer trial

EpiSwitch will be trialled for the blood-based diagnosis of prostate cancer. Credit: qimono via Pixabay.



  • Oxford BioDynamics to assess EpiSwitch in prostate cancer trial